Jhalak Dholakia, MD
Gynecologic Oncology · Greenville, NCNPI 1902253446
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,375 of the $5,503 with a category attached, or 61.3%. AbbVie accounts for 82.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,537, more than ten times the $244 reported in 2019.
Across 21 payments — averaging $262.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$261
- Merck$178
- GSK$141
- Tesaro, Inc.$125
- Genmab U.S., Inc.$123
- plus $154 from 3 others
What the payments were for
- Consulting fees$3,37561%
- Travel & lodging$1,00318%
- Food & beverage$1,03119%
- Education$952%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $4,522 |
| AstraZeneca | 3 | $261 |
| Merck | 5 | $178 |
| GSK | 2 | $141 |
| Tesaro, Inc. | 1 | $125 |
| Genmab U.S., Inc. | 1 | $123 |
| Intuitive Surgical | 1 | $100 |
| Seagen Inc. | 1 | $38 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,503 in reported general payments places this provider in the 70th percentile of 52 gynecologic oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $19,069 |
| Gabapentin | 37 | $270 |
| Prochlorperazine Maleate | 26 | $249 |
| Ondansetron OdtOndansetron | 15 | $195 |
| Potassium Chloride | 16 | $148 |
| Oxycodone Hcl | 13 | $147 |
| Ondansetron Hcl | 19 | $89 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Greenville
- Diane SemerGreenville$1K
- Lucybeth Nieves ArribaWilmington$251K
- Robert NaumannCharlotte$221K
- Angeles SecordDurham$121K
- Erin CraneCharlotte$98K
- Michael SundborgSouthern Pines$85K
- William LoweryDurham$67K
- Emma RossiGreensboro$62K
- Jubilee BrownCharlotte$44K
- Victoria Bae-JumpChapel Hill$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.